Danaparoid

Danaparoid

Clinical data
ATC code	B01AB09 (WHO)
Identifiers
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}

WikiDoc Resources for Danaparoid
Articles
Most recent articles on Danaparoid Most cited articles on Danaparoid Review articles on Danaparoid Articles on Danaparoid in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Danaparoid Images of Danaparoid Photos of Danaparoid Podcasts & MP3s on Danaparoid Videos on Danaparoid
Evidence Based Medicine
Cochrane Collaboration on Danaparoid Bandolier on Danaparoid TRIP on Danaparoid
Clinical Trials
Ongoing Trials on Danaparoid at Clinical Trials.gov Trial results on Danaparoid Clinical Trials on Danaparoid at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Danaparoid NICE Guidance on Danaparoid NHS PRODIGY Guidance FDA on Danaparoid CDC on Danaparoid
Books
Books on Danaparoid
News
Danaparoid in the news Be alerted to news on Danaparoid News trends on Danaparoid
Commentary
Blogs on Danaparoid
Definitions
Definitions of Danaparoid
Patient Resources / Community
Patient resources on Danaparoid Discussion groups on Danaparoid Patient Handouts on Danaparoid Directions to Hospitals Treating Danaparoid Risk calculators and risk factors for Danaparoid
Healthcare Provider Resources
Symptoms of Danaparoid Causes & Risk Factors for Danaparoid Diagnostic studies for Danaparoid Treatment of Danaparoid
Continuing Medical Education (CME)
CME Programs on Danaparoid
International
Danaparoid en Espanol Danaparoid en Francais
Business
Danaparoid in the Marketplace Patents on Danaparoid
Experimental / Informatics
List of terms related to Danaparoid

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Danaparoid sodium (Orgaran®) is an anticoagulant that works by inhibiting activated factor X (factor Xa).

Danaparoid is considered a "low molecular weight heparin" by some sources, but is chemically distinct from heparin and thus has little cross-reactivity in heparin-intolerant patients.

Uses

It is used to prevent deep venous clots, particularly in situations with a high risk of clot formation, such as after hip surgery.

It is also used as a heparinoid substitute in heparin-induced thrombocytopenia which may otherwise cause paradoxical thrombosis.

Discontinuation

On August 14, 2002, this drug was withdrawn by Organon International.

Administration

• IV
• SC

Side Effects

• Bleeding problems
• Low platelets, due to a low level of structural similarity between danaparoid and heparin
• Asthma exacerbations, due to allergies to sulphites contained within the medicine

External Links

• danaparoid at the US National Library of Medicine Medical Subject Headings (MeSH)